[en] Ultrasound biometry data were used for a treatment planning computer program that allows three-dimensional viewing of the eye containing a uveal melanoma. This program enables one to select an orientation of the eye relative to the path of the proton beam which best covers the tumor while avoiding important ocular structures. (Auth.)

No abstract available

[en] Investigations in proton beam therapy of cancer patients have been initiated at the Cyclotron Laboratory, Harvard University, Cambridge, USA, since 1974 using a proton beam the energy of 180 MeV for fractionated irradition of uveal melanoma (899 cases), chordoma and chondrosarcoma of the base of the skull (96), sarcoma of the soft tissues and bones (79), prostatic cancer, head and neck tumors, etc. (altogether 1331 patients had been irradiated by June, 1986). Proton beam therapy is used alone or in combination with proton beam irradiation, routine radiotherapy. Areas of particular interset are ocular melanoma, chordoma and chondrosarcoma of the base of the skull, paraspinal sarcomas. Investigations in the field of proton beam therapy of malignant meningioma, metastases to the paraaortic lymph nodes hold promise

[en] Proton beam treatment techniques provide a powerful approach to improving dose distribution (decrease treatment volume towards target volume) and hence increasing dose to target with resultant higher tumor control rates and lesser morbity. To achieve these dose distributions in patients requires use of modern imaging techniques, rigid immobilization systems, confirmation of target position vis a vis the proton beam at each treatment session, treatment planning which feature beam's eye view, displays of uncertainty, dose at each anatomic point, boli based on accurate assessment of density along each pixel, etc. Experience at MGH/MEEI/HCL has yielded a disease-free survival of 78% for patients with chordoma/chondrosarcoma of base of skull. Local control is achieved by 98% of patients treated for choroidal melanoma. (orig.)